<SEC-DOCUMENT>0001193125-22-121449.txt : 20220602
<SEC-HEADER>0001193125-22-121449.hdr.sgml : 20220602
<ACCEPTANCE-DATETIME>20220427061058
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-22-121449
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Haymaker Acquisition Corp. III
		CENTRAL INDEX KEY:			0001819253
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		1875 W. WALNUT HILL LN #100
		CITY:			IRVING
		STATE:			TX
		ZIP:			75038
		BUSINESS PHONE:		972-486-9346

	MAIL ADDRESS:	
		STREET 1:		1875 W. WALNUT HILL LN #100
		CITY:			IRVING
		STATE:			TX
		ZIP:			75038

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Haymaker Acquisition Corp. III
		DATE OF NAME CHANGE:	20200727
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="7">


<IMG SRC="g229585g0329121432924.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>DLA Piper LLP (US)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1251 Avenue of the Americas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, NY 10020-1104</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">www.dlapiper.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sidney Burke</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sidney.Burke@dlapiper.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>T</B>&nbsp;&nbsp;212.335.4509</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">April 27, 2022</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>VIA EDGAR </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States
Securities and Exchange Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street, N.E. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Judiciary Plaza </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tracie Mariner</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Angela Connell</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Daniel Crawford</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Celeste Murphy</P></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Haymaker Acquisition Corp. III </B></P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Revised Preliminary Proxy Statement on Schedule 14A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Filed April&nbsp;8, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40128</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Mses. Mariner, Connell and Murphy and Mr.&nbsp;Crawford: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This letter is submitted on behalf of Haymaker Acquisition Corp. III (the &#147;<U>Company</U>&#148;) in response to the comments of the staff
of the Division of Corporation Finance (the &#147;<U>Staff</U>&#148;) of the Securities and Exchange Commission with respect to the above-referenced Revised Preliminary Proxy Statement on Schedule 14A filed on April&nbsp;8, 2022 (the
&#147;<U>Preliminary Proxy Statement</U>&#148;), as set forth in your letter dated April&nbsp;20, 2022, addressed to Steven J. Heyer, Chief Executive Officer and Chairman of the Company (the &#147;<U>Comment Letter</U>&#148;). The Company is
concurrently filing Amendment No.&nbsp;2 to the Preliminary Proxy Statement (the &#147;<U>Second Amended Proxy Statement</U>&#148;), which includes changes that reflect responses to the Staff&#146;s comments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The responses provided herein are based upon information provided to DLA Piper LLP (US) by the Company. For reference purposes, the text of
the Comment Letter has been reproduced herein with the response below the comment. For your convenience, we have italicized the reproduced Staff comments from the Comment Letter. Defined terms used in this letter not otherwise defined have the
meanings ascribed to such terms in the Second Amended Proxy Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Revised Preliminary Proxy Statement filed April&nbsp;8, 2022. </U></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Information About Biote </U></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 27, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>What We Offer </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Biote Business Model/Solution, page 240 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note Exhibit No.&nbsp;99.1 in your report dated March&nbsp;29, 2022 on form <FONT
STYLE="white-space:nowrap">8-K</FONT> provides additional detail on Biote&#146;s business. For example, page 11 makes it appear Biote&#146;s hormone therapy solution does not include
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> pills, prescription creams, patches, pills, or injectables, but instead, uses pellet implants as described by the graphic on page 11 that appears to
show hormone pellets held in a person&#146;s hand and the corresponding text above the hand. As another example, we note on page 49 that Biote charges a service fee averaging $180 for every hormone optimization procedure, accounting for 79% of
Biote&#146;s revenue. Please revise your proxy statement here to disclose the methods of hormone optimization (e.g., pellet implants, prescription pills) used by your practitioners that entitle Biote to service fees. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>The Company acknowledges the Staff&#146;s comment and has modified its disclosure on pages 242, 246, 247, 248 and 251 of the
Second Amended Proxy Statement as requested. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Competition, page 252 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>2.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your response to comment 23 and reissue in part. Please revise your disclosure to provide more
detail on the competition you face in the dietary supplement space. For example only, disclose whether there are other competitors that sell branded dietary supplements through certified practitioners and identify them. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>The Company acknowledges the Staff&#146;s comment and has modified its disclosure on pages 64 and 258 of the Second Amended
Proxy Statement as requested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page immediately follows.] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 27, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you have any questions regarding the foregoing responses or otherwise, please do not
hesitate to call me at (212) <FONT STYLE="white-space:nowrap">335-4509</FONT> or Stephen P. Alicanti at (212) <FONT STYLE="white-space:nowrap">335-4783.</FONT> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>DLA Piper LLP (US)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Sidney Burke</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sidney Burke</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Partner</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Christopher Bradley, Haymaker Acquisition Corp. III </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stephen P. Alicanti, DLA Piper LLP (US) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Michal Berkner, Cooley LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ryan
Sansom, Cooley LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Peter Byrne, Cooley LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g229585g0329121432924.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g229585g0329121432924.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !& '@# 2(  A$! Q$!_\0
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C'U>6U9U:"E-W=V%%%%<1WA1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
